标记临床研究 XOMA 深 沪
已收盘 07-02 16:00:00 美东时间
43.00
+0.380
+0.89%
华盛通- 最 高43.00
- 今 开42.62
- 成交量 13.77万股
- 最 低 42.46
- 昨 收 42.62
- 总市值 7.60亿
- 52周最高 43.00
- 市盈率 静 29.53
- 换手率 0.78%
- 52周最低 22.29
- 委 比 -12.47%
- 总股本 1767.87万
- 历史最高 191.40
- 量 比 0.55
- 振 幅 1.27%
- 历史最低 3.96
- 每 手 1
- 风险率 6.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ligand prices proposed $550M convertible senior notes offering
Ligand Pharmaceuticals (LGND) said on Monday it plans to offer $550M of convertible senior notes due 2031 in a private placement and expects to grant initial purchasers a 13-day option to buy up to an...
06-22 19:33
XOMA Details Merger Timeline and Preferred Share Redemption
An update from XOMA Royalty Corporation ( ($XOMA) ) is now available. On June 1...
06-13 07:53
XOMA Preferred Shares Series A declares $0.539 dividend
XOMA Preferred Shares Series A (XOMAP) declares $0.539/share quarterly dividend, in line with previous. Forward yield 8.47% Payable July 15; for shareholders of record July 2; ex-div July 2. See XOMAP...
06-13 04:14
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
XOMA Royalty Corporation announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Preferred Stock, with dividends of $0.53906 per share for Series A and $0.52344 per depositary share for Series B. The Preferred Stock will be redeemed on July 14, 2026, at $25.00 per share or depositary share. Dividends will be paid on July 15, 2026, to holders of record as of July 2, 2026. The redemption is part ...
06-12 20:05
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
An announcement from XOMA Royalty Corporation ( ($XOMA) ) is now available. On ...
05-18 22:08
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to acquire XOMA Royalty for $39 per share, totaling $739 million. The deal adds over 120 assets, including 7 commercial products and nearly doubles Ligand's Phase 2 and 3 pipeline. Ligand expects the transaction to be immediately accretive to EPS, raising 2026 adjusted EPS guidance to $8.50-$9.50 and adding $1.50 per share in 2027. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and stockhol...
04-27 11:00
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
